Pfizer Announces Positive Top-Line Results from the Comparative REFLECTIONS B538-02 Study for a Potential Biosimilar to Humira (adalimumab), PF-06410293
January 5, 2017
Pfizer Inc. has announced that the confirmatory REFLECTIONS B538-02 study met its primary objective by demonstrating equivalent efficacy as measured by the American College of Rheumatology 20 (ACR20) response rate at Week 12. This trial is evaluating the safety, efficacy, and immunogenicity of PF-06410293 compared to Humira® (adalimumab), each taken in combination with methotrexate, in patients with moderate to severe rheumatoid arthritis. PF-06410293 is being developed as a potential biosimilar to Humira.
Jan 09, 2017
AbbVie, a global biopharmaceutical company, has announced four new collaborations and investments with leading healthcare innovators for advancing early-stage research in key therapeutic areas such as immunology and oncology. The company is committed to investing in and developing transformational science and technologies to advance the next-generation of therapies across its robust pipeline in key therapeutic areas.
January 9, 2017
Takeda, a prominent Japanese drugmaker, provided the first major deal of the J.P. Morgan Healthcare Conference. The company announced a takeover of Ariad Pharmaceuticals which valued the cancer specialist at $5.2 billion.
January 9, 2017
Ipsen will gain exclusive commercialization rights for the current and potential future of ONIVYDE indications in the U.S. The transaction also includes the commercial and manufacturing infrastructure of Merrimack, and generic doxorubicin HCl liposome injection. The transaction represents a unique opportunity and a strong strategic fit for Ipsen. ONIVYDE is an FDA-approved and clinically differentiated product for treating metastatic pancreatic cancer in adult patients.
Jan. 9, 2017
Amgen and Immatics Biotechnologies, a leading company in the field of cancer immunotherapy, have announced a research collaboration and exclusive license agreement for developing next-generation, T-cell engaging bispecific immunotherapies targeting multiple cancers. The collaboration will combine Amgen’s validated Bispecific T-cell Engager (BiTE®) technology with Immatics’ world-leading XPRESIDENT® target discovery and T-cell receptor (TCR) capabilities with the goal of creating novel oncology drugs. Amgen will be responsible for the clinical development, manufacturing and commercialization globally.
FDA grants Roche’s cancer immunotherapy TECENTRIQ (atezolizumab) Priority Review for the treatment of advanced bladder cancer
09 January 2017
Roche has announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) of the company and granted Priority Review for TECENTRIQ® (atezolizumab) for the treatment of people with locally advanced or metastatic urothelial carcinoma (mUC) who are ineligible for cisplatin chemotherapy, and are either previously untreated (first-line) or have disease progression at least 12 months after receiving chemotherapy before surgery (neoadjuvant) or after surgery (adjuvant). Urothelial carcinoma accounts for 90 percent of all bladder cancers and can also be found in the renal pelvis, ureter and urethra.
January 10, 2017
Allergan has announced that it has reached separate agreements to partner with both Lysosomal Therapeutics and Assembly Biosciences for research and development. These announcements were released at the J.P. Morgan Healthcare Conference 2017.
Jan. 11, 2017
Eli Lilly and Company has announced the expansion of an existing immuno-oncology collaboration with Merck, known as MSD outside the U.S. and Canada, to add a new study of LARTRUVO™ (olaratumab) of Lilly with Merck’s KEYTRUDA® (pembrolizumab) in patients with previously treated advanced or metastatic soft tissue sarcoma (STS).
Jan 15, 2017
ABBVIE ANNOUNCES FOUR NEW GLOBAL RESEARCH COLLABORATIONS January 9, 2017 AbbVie, a global biopharmaceutical company, has announced four new collaborations and investments with leading healthcare innovators for advancing early-stage research in key therapeutic areas such as immunology and oncology.
17 January 2017
AstraZeneca has provided an update on its Immuno-Oncology (IO) late-stage clinical development programme in 1st-line non-small cell lung cancer (NSCLC), including a refinement of the Phase III MYSTIC trial.
Jan. 18, 2017
Eli Lilly and Company and CoLucid Pharmaceuticals, Inc. has announced an agreement for Lilly to acquire CoLucid for $46.50 per share or nearly $960 million. This all-cash transaction will enhance the existing portfolio of Lilly in pain management for migraine. The transaction is expected to close by the end of the first quarter of 2017.
Eisai plots new drug applications in US, Europe and China after Lenvima scores in head-to-head liver cancer study
January 25, 2017
Eisai says that its cancer drug Lenvima (lenvatinib) hit the primary endpoint in a Phase III study for the treatment of liver cancer, proving non-inferior to Nexavar. That success will set up regulatory filings in the US, Europe and Asia, the company adds. Liver cancer is a particularly big problem in China, where Eisai plans to roll out an application in the near future.
Jan 26, 2017
Johnson & Johnson (J&J) has said that it is going to buy Swiss biotech Actelion Pharmaceuticals for $30 billion. The company also plans to spin out its research and development unit into a separate business. The deal is expected to close in mid-February.
You may also be interested in the following analyses and perspectives:
In 2016, the Center for Drug Evaluation and Research (CDER) of FDA approved 22 novel drugs. This represents a significant slowdown compared to the 45 new medications in 2015 and 41 in 2014. Despite the negative trend of approval over the past few years, we are still going to see many launches in 2017.
Merck, known as MSD outside the United States and Canada, offers health solutions through its prescription medicines, vaccines, and biologic
Hoffmann-La Roche (Roche) develops, manufactures and deliver innovative therapeutics and diagnostic instruments and tests. The company operates through two business segments: Pharmaceuticals and Diagnostics.
Pfizer is a research-based pharmaceutical company engaged in the wellness, prevention and treatment for diseases across a broad range of therapeutic areas. The company operates through Innovative Health and Established Health businesses.
The top-ten oncology drugs accounted for 36% of the total oncology drugs market. The list is headed by Avastin, an oncology product manufactured by Roche
What is the fair salary for a Sales Rep in US? And for a Brand Manager in Europe? What about a CRA in India? There are a wide range of jobs in the pharmaceutical industry and their pay varies greatly.